Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart

European Journal of Heart Failure

Volumn 10, Issue 12, 2008, Pages 1158-1165

  Andersen, Asger ^a   Nielsen, Jan Møller ^a   Peters, Christian Daugaard ^b   Schou, Uffe Kjær ^b   Sloth, Erik ^a   Nielsen Kudsk, Jens Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Echocardiography; Pulmonary hypertension; Pulmonary trunk banding; Right ventricular failure; Right ventricular hypertrophy; Sildenafil

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; LONG TERM CARE; LUNG ARTERY BANDING; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ECHOCARDIOGRAPHY; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SULFONES; VENTRICULAR FUNCTION, RIGHT;

EID: 56349169853     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.09.016     Document Type: Article

References (31)

1. McLaughlin V.V., and Rich S. Pulmonary hypertension. Curr Probl Cardiol 29 10 (2004) 575-634
2. Davlouros P.A., Niwa K., Webb G., and Gatzoulis M.A. The right ventricle in congenital heart disease. Heart 92 Suppl 1 (2006) i27-i38
3. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7 8 (2006) 589-600
4. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 24 (2004) 2243-2278
5. Roos-Hesselink J.W., Meijboom F.J., Spitaels S.E., et al. Decline in ventricular function and clinical condition after Mustard repair for transposition of the great arteries (a prospective study of 22-29 years). Eur Heart J 25 14 (2004) 1264-1270
6. K.M. Chin, N.H. Kim, L.J. Rubin, The right ventricle in pulmonary hypertension. Coronary artery disease 5 A.D.;(0954-6928 (Print)).
7. Kishimoto I., Rossi K., and Garbers D.L. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A 98 5 (2001) 2703-2706
8. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 2 (2005) 214-222
9. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 20 (2005) 2148-2157
10. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105 20 (2002) 2398-2403
11. M.R. Wilkins, G.A. Paul, J.W. Strange, et al, Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.(1073-449X (Print)).
12. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., and Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 25 (2003) 3230-3235
13. R.T. Schermuly, K.P. Kreisselmeier, H.A. Ghofrani, et al., Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.(1073-449X (Print)).
14. Schou U.K., Peters C.D., Wan Kim S., Frokiaer J., and Nielsen S. Characterization of a rat model of right-sided heart failure induced by pulmonary trunk banding. J Exp Ani Sci 43 4 (2007) 237-254
15. Clozel M., Hess P., Rey M., et al. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231 6 (2006) 967-973
16. Walker D.K., Ackland M.J., James G.C., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29 3 (1999) 297-310
17. Kaul S., Tei C., Hopkins J.M., and Shah P.M. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 107 3 (1984) 526-531
18. Hardziyenka M., Campian M.E., de Bruin-Bon H.A., Michel M.C., and Tan H.L. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr 19 10 (2006) 1272-1279
19. S. Ghio, F.F. Recusani, C.F. Klersy, et al., Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy.(0002-9149 (Print)).
20. J.F. Kjaergaard, D.F. Akkan, K.K. Iversen, et al., Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure.(1388-9842 (Print)).
21. W.F. Qin, A.E. Rudolph, B.R. Bond, et al., Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.(1524-4571 (Electronic)).
22. K.F. Swedberg, P.F. Eneroth, J.F. Kjekshus, L. Wilhelmsen, Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.(0009-7322 (Print)).
23. Kappelgaard A.M., Nielsen M.D., and Giese J. Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 67 3 (1976) 299-306
24. Rask-Madsen J., Bruusgaard A., Munck O., Nielsen M.D., and Worning H. The significance of bile acids and aldosterone for the electrical hyperpolarization of human rectum in obese patients treated with intestinal bypass operation. Scand J Gastroenterol 9 5 (1974) 417-426
25. A.F. Lopez-Candales, K.F. Dohi, et al., Defining normal variables of right ventricular size and function in pulmonary hypertension: an echocardiographic study.(1469-0756 (Electronic)).
26. A.A. Karatza, A.F. Bush, A.G. Magee, Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.(0167-5273 (Print)).
27. Shin H.S., Bae S.K., and Lee M.G. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm 320 1-2 (2006) 64-70
28. N.F. Voelkel, R.A. Quaife, L.A. Leinwand, et al., Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.(1524-4539 (Electronic)).
29. Zaffran S., Kelly R.G., Meilhac S.M., Buckingham M.E., and Brown N.A. Right ventricular myocardium derives from the anterior heart field. Circ Res 95 3 (2004) 261-268
30. Usui S., Yeh I., Tian B., and Sadoshima J. Global changes in gene expression during cardiac hypertrophy: a new direction of cardiac signaling research. J Mol Cell Cardiol 41 2 (2006) 219-222
31. Nagendran J., Archer S.L., Soliman D., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116 3 (2007) 238-248